Related Experiment Video
Updated: Dec 12, 2025
Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
Published on: March 8, 2012
Human papillomavirus vaccine effectiveness within a cervical cancer screening programme: cohort study
C Acuti Martellucci1, S Nomura1, D Yoneoka1,2
1Department of Global Health Policy, School of International Health, Graduate School of Medicine, The University of Tokyo, Bunkyo City, Tokyo, Japan.
Objective:
To assess the effectiveness of an HPV vaccination programme in reducing the risk of cervical abnormalities identified at subsequent screening.
Design:
Retrospective cohort study using administrative health data.
Setting:
General population of Ferrara Province, Italy.
Population:
Female residents born in 1986-1993 and participating in the organized cervical screening programme in 2011-2018, who were eligible for HPV vaccination in catch-up cohorts.
Methods:
Logistic regression to evaluate the potential association between abnormal cervical cytology and one, two, three or at least one dose of HPV vaccine.
Main Outcome Measures:
Cervical abnormalities, as predicted by low-grade or high-grade cytology, by number of vaccine doses, stratified by age.
Results:
The sample consisted of 7785 women (mean age 27.5 years, SD 2.3). Overall, 391 (5.0%) were vaccinated with ≥1 dose and 893 (11.5%) had abnormal cytology. Women receiving at least one vaccine dose were significantly less likely to have an abnormal cytology (adjusted odds ratio 0.52; 95% confidence interval 0.34-0.79). Similar results were observed for women receiving a single dose, for both bivalent and quadrivalent vaccines, and applying buffer periods (excluding cytological outcomes within 1 month, 6 months and 1 year of the first dose).
Conclusions:
In the context of an organised cervical screening programme in Italy, catch-up HPV vaccination almost halved the risk of cytological abnormalities.
Tweetable Abstract:
Among Ferrara women, vaccination against human papillomavirus halved the risk of screening cervical abnormalities.
